    <SEC-DOCUMENT>0001193125-26-168538-index.html : 20260422
    <SEC-HEADER>0001193125-26-168538.hdr.sgml : 20260422
    <ACCEPTANCE-DATETIME>20260422080425
    ACCESSION NUMBER:		0001193125-26-168538
    CONFORMED SUBMISSION TYPE:	ARS
    PUBLIC DOCUMENT COUNT:		1
    CONFORMED PERIOD OF REPORT:	20251231
    FILED AS OF DATE:		20260422
    DATE AS OF CHANGE:		20260422
    EFFECTIVENESS DATE:		20260422

    FILER:

    	COMPANY DATA:
    		COMPANY CONFORMED NAME:			Taysha Gene Therapies, Inc.
    		CENTRAL INDEX KEY:			0001806310
    		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
    		ORGANIZATION NAME:           	03 Life Sciences
    		EIN:				843199512
    		STATE OF INCORPORATION:			DE
    		FISCAL YEAR END:			1231

    	FILING VALUES:
    		FORM TYPE:		ARS
    		SEC ACT:		1934 Act
    		SEC FILE NUMBER:	001-39536
    		FILM NUMBER:		26881331

    	BUSINESS ADDRESS:
    		STREET 1:		3000 PEGASUS PARK DRIVE
    		STREET 2:		SUITE 1430
    		CITY:			DALLAS
    		STATE:			TX
    		ZIP:			75247
    		BUSINESS PHONE:		(214) 612-0000

    	MAIL ADDRESS:
    		STREET 1:		3000 PEGASUS PARK DRIVE
    		STREET 2:		SUITE 1430
    		CITY:			DALLAS
    		STATE:			TX
    		ZIP:			75247
    </SEC-HEADER>
    <DOCUMENT>
    <TYPE>ARS
    <SEQUENCE>1
    <FILENAME>d942601dars.pdf
    <DESCRIPTION>ARS
    <TEXT>
    Document 1 - file: d942601dars.pdf

    </DOCUMENT>
    </SEC-DOCUMENT>